Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W9AI
|
||||
| Former ID |
DIB013371
|
||||
| Drug Name |
MTC-DOX
|
||||
| Synonyms |
MTC-doxorubicin
|
||||
| Indication | Liver cancer [ICD9: 140-229, 155, 203.0; ICD10:C22] | Phase 2/3 | [1] | ||
| Company |
FeRx
|
||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.